Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.69 USD | +5.94% | +0.58% | 0.00% |
Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 15M | Capitalization | 372M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 99.6M | Net cash position 2025 * | 53.37M | EV / Sales 2025 * | 21.3 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.81% |
1 day | +1.28% | ||
1 week | -2.91% | ||
Current month | -3.85% | ||
1 month | -1.64% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 15.69 | +5.94% | 114 154 |
24-05-07 | 14.81 | -0.07% | 77,411 |
24-05-06 | 14.82 | +5.18% | 34,593 |
24-05-03 | 14.09 | -5.44% | 99,564 |
24-05-02 | 14.9 | -3.56% | 92,571 |
Delayed Quote Nasdaq, May 08, 2024 at 01:25 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 372M | |
+22.55% | 46.4B | |
-1.68% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+9.89% | 26.01B | |
-19.34% | 19.52B | |
+29.07% | 12.43B | |
-0.01% | 12.18B | |
-0.58% | 12.13B |
- Stock Market
- Equities
- CTNM Stock